Trials / Not Yet Recruiting
Not Yet RecruitingNCT06811220
The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is evaluation of the potential neuroprotective effect of oral hesperidin and diosmin in reducing paclitaxel- induced peripheral neuropathy in the treatment of breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hespiridin and Diosmin | Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet) |
Timeline
- Start date
- 2025-01-27
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
- First posted
- 2025-02-06
- Last updated
- 2025-02-06
Source: ClinicalTrials.gov record NCT06811220. Inclusion in this directory is not an endorsement.